Show simple item record

AuthorAli, Zainab Omer
AuthorBader, Loulia
AuthorMohammed, Shaaban
AuthorArafa, Salaheddin
AuthorArabi, Abdulrahman
AuthorCavallari, Larisa
AuthorLangaee, Taimour
AuthorMraiche, Fatima
AuthorRizk, Nasser
AuthorAwaisu, Ahmed
AuthorShahin, Mohamed H.
AuthorElewa, Hazem
Available date2022-12-15T07:16:22Z
Publication Date2022
Publication NamePharmacogenetics and Genomics
ResourceScopus
URIhttp://dx.doi.org/10.1097/FPC.0000000000000469
URIhttp://hdl.handle.net/10576/37299
AbstractIntroduction One-third of patients have clopidogrel resistance that may lead to major adverse cardiac events (MACEs). By contrast, it was found that some clopidogrel-treated patients have hyperresponsive platelets that are associated with higher bleeding risk. Several studies have shown that polymorphisms in the gene encoding the CYP2C19 contribute to the variability in response to clopidogrel. Data on genetic and nongenetic factors affecting clopidogrel response in the Arab population are scarce. In this prospective cohort study, we sought to assess the association between the increased function allele (CYP2C19?17) and bleeding events, and validate the effect of the CYP2C19 genetic variants and nongenetic factors on the incidence of MACEs. Methods Blood samples were collected from patients that were undergoing percutaneous coronary intervention and receiving clopidogrel at the Heart Hospital, a specialist tertiary hospital in Doha, Qatar. Patients were followed for 12 months. Genotyping was performed for CYP2C19?2, ?3, and ?17 using TaqMan assays. Results In 254 patients, the minor allele frequencies were 0.13, 0.004, and 0.21 for ?2, ?3, and ?17, respectively. Over a 12-month follow-up period, there were 21 bleeding events (8.5 events/100 patient-year). CYP2C19?17 carriers were found to be associated with increased risk of bleeding (OR, 21.6; 95% CI, 4.8-96.8; P < 0.0001). CYP2C19?2 or ?3 carriers were found to be associated with increased risk of baseline and incident MACE combined (OR, 8.4; 95% CI, 3.2-23.9; P < 0.0001). Conclusion This study showed a significant association between CYP2C19?17 allele and the increased risk of bleeding, and CYP2C19?2 or ?3 with MACE outcomes. 2022 Lippincott Williams and Wilkins. All rights reserved.
SponsorThe author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was funded by Hamad Medical Corporation, Doha, Qatar (grant number: IRGC-02-NI-052). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Languageen
PublisherLippincott Williams and Wilkins
Subjectantiplatelets
bleeding
clopidogrel
CYP2C19
pharmacogenomics
thrombosis
TitleEffect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation
TypeArticle
Pagination183-191
Issue Number5
Volume Number32
dc.accessType Abstract Only


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record